Fortrea Holdings FTRE
NASDAQ FTRE
$17.70 -0.92 (-4.94%)
As of: Sep 4, 2026 · 3:59 PM EDT

Fortrea Holdings (FTRE) Income from Continuing Operations (2022 - 2026)

Fortrea Holdings' (FTRE) quarterly Income from Continuing Operations came in at 13200000.0 in Q2 2026, up 96.48% YoY from 6718273.15 in Q2 2025, and up 44.07% on a QoQ basis from 23600000.0 in Q1 2026.

Analysis

Fortrea Holdings (FTRE) Income from Continuing Operations (2022 - 2026) Analysis & Trends

Fortrea Holdings (FTRE) has 5 years of Income from Continuing Operations data on file, last reported at 13200000.0 in Q2 2026.

  • Quarterly Income from Continuing Operations rose 96.48% year-over-year to 13200000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 85200000.0 (up 91.73% YoY) and the FY2025 annual result came in at 986200000.0, down 263.24% from the prior year.
  • Income from Continuing Operations improved to 13200000.0 in Q2 2026, from 23600000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 66400000.0 in Q2 2022 to a low of 562900000.0 in Q1 2025.
  • A 5-year average of 71341176.47 and a median of 18500000.0 in 2024 frame the typical range for Income from Continuing Operations.
  • Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 1097.5% — and 2026, when it surged 96.48%.
  • Tracing FTRE's Income from Continuing Operations over 5 years: stood at 13600000.0 in 2022, then slumped by 257.35% to 48600000.0 in 2023, then sank by 52.06% to 73900000.0 in 2024, then soared by 56.02% to 32500000.0 in 2025, then surged by 59.38% to 13200000.0 in 2026.
  • The last three Income from Continuing Operations figures came in at 13200000.0 (Q2 2026), 23600000.0 (Q1 2026), and 32500000.0 (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -13.27 Mn
10 Fortrea Holdings 1.68 Bn 1.51 Bn 139.20 Mn -13.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -13.20 Mn
Mar 31, 2026 -23.60 Mn
Dec 31, 2025 -32.50 Mn
Sep 30, 2025 -15.90 Mn
Jun 30, 2025 -374.90 Mn
Mar 31, 2025 -562.90 Mn
Dec 31, 2024 -73.90 Mn
Sep 30, 2024 -18.50 Mn
Jun 30, 2024 -99.30 Mn
Mar 31, 2024 -79.80 Mn
Dec 31, 2023 -48.60 Mn
Sep 30, 2023 -16.10 Mn
Jun 30, 2023 25.00 Mn
Mar 31, 2023 8.00 Mn
Dec 31, 2022 -13.60 Mn
Sep 30, 2022 60.60 Mn
Jun 30, 2022 66.40 Mn